Sociodemographic Characteristics of Participants Stratified by Dosing Schedulea
| . | 0–2 y Since 1st Dose (n = 136) . | 2–3 y Since 1st Dose (n = 108) . | 3–4 y Since 1st Dose (n = 97) . | 4–4½ y Since 1st Dose (n = 90) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | 3 Doses (n = 83) . | 2 Doses (n = 53) . | P Value . | 3 Doses (n = 77) . | 2 Doses (n = 29) . | P Value . | 3 Doses (n = 68) . | 2 Doses (n = 29) . | P Value . | 3 Doses (n = 70) . | 2 Doses (n = 20) . | P Value . |
| Current educational level, No. (%) | ||||||||||||
| Low | 14 (17) | 12 (23) | .49 | 11 (14) | 9 (31) | .23 | 9 (13) | 3 (10) | .82 | 4 (6) | 0 (0) | .45 |
| Middle | 21 (25) | 13 (25) | 22 (29) | 6 (21) | 24 (35) | 12 (41) | 32 (46) | 7 (35) | ||||
| High | 48 (58) | 27 (51) | 43 (56) | 14 (48) | 35 (51) | 14 (48) | 34 (49) | 13 (65) | ||||
| Unknown | 0 (0) | 1 (2) | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Country of birth, No. (%) | ||||||||||||
| Netherlands | 79 (100) | 49 (98) | .39 | 72 (97) | 26 (96) | .32 | 68 (100) | 28 (97) | .30 | 68 (97) | 17 (85) | .03 |
| Europe | 0 (0) | 0 (0) | 2 (3) | 0 (0) | 0 (0) | 1 (3) | 2 (3) | 1 (5) | ||||
| Other | 0 (0) | 1 (2) | 0 (0) | 1 (4) | 0 (0) | 0 (0) | 0 (0) | 2 (10) | ||||
| Country of birth mother, No. (%) | ||||||||||||
| Netherlands | 80 (96) | 45 (85) | .05 | 73 (95) | 22 (76) | <.01 | 65 (96) | 22 (76) | .01 | 63 (90) | 17 (85) | .70 |
| Europe | 1 (1) | 2 (4) | 3 (4) | 2 (7) | 1 (1) | 2 (7) | 3 (4) | 1 (5) | ||||
| Other | 2 (2) | 6 (11) | 1 (1) | 5 (17) | 2 (3) | 4 (14) | 4 (6) | 2 (10) | ||||
| Unknown | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | ||||
| Country of birth father, No. (%) | ||||||||||||
| Netherlands | 79 (95) | 45 (87) | .17 | 75 (97) | 18 (62) | <.01 | 66 (97) | 22 (76) | <.01 | 65 (93) | 15 (75) | .03 |
| Europe | 1 (1) | 1 (2) | 2 (3) | 2 (7) | 1 (1) | 1 (3) | 2 (3) | 0 (0) | ||||
| Other | 3 (4) | 6 (12) | 0 (0) | 8 (28) | 1 (1) | 5 (17) | 3 (4) | 5 (25) | ||||
| Unknown | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | ||||
| Oral contraceptive use, No. (%) | ||||||||||||
| Current user | 4 (5) | 4 (8) | .87 | 10 (13) | 9 (31) | .08 | 27 (40) | 14 (48) | .20 | 51 (73) | 13 (65) | .69 |
| Past user | 2 (2) | 1 (2) | 2 (3) | 0 (0) | 1 (1) | 2 (7) | 5 (7) | 1 (5) | ||||
| No | 77 (93) | 48 (91) | 65 (84) | 20 (69) | 40 (59) | 13 (45) | 14 (20) | 6 (30) | ||||
| Ever had sex, No. (%) | ||||||||||||
| Never | 82 (99) | 51 (96) | .56 | 71 (92) | 26 (90) | .43 | 57 (84) | 19 (66) | .06 | 37 (53) | 12 (60) | .62 |
| Yes | 1 (1) | 2 (4) | 6 (8) | 2 (7) | 11 (16) | 10 (34) | 33 (47) | 8 (40) | ||||
| Don’t know | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Age at sexual debut, median (range), y | 15 (15-15) | 14 (14-14) | .16 | 14 (13–15) | 14.5 (14–15) | .82 | 15 (13–16) | 15 (15-15) | .90 | 15 (12–16) | 16 (13–17) | .37 |
| Immuuncompromised, No. (%) | ||||||||||||
| No | 82 (99) | 53 (100) | >.99 | 77 (100) | 29 (100) | >.99 | 68 (100) | 29 (100) | >.99 | 70 (100) | 20 (100) | >.99 |
| Yes | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Don’t Know | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Immuunsupressive medication, No. (%) | ||||||||||||
| No | 79 (95) | 53 (100) | .41 | 74 (96) | 29 (100) | .56 | 61 (90) | 29 (100) | .27 | 67 (96) | 19 (95) | >.99 |
| Yes | 2 (2) | 0 (0) | 0 (0) | 0 (0) | 4 (6) | 0 (0) | 0 (0) | 0 (0) | ||||
| Don’t know | 2 (2) | 0 (0) | 3 (4) | 0 (0) | 3 (4) | 0 (0) | 3 (4) | 1 (5) | ||||
| Had menarche, No. (%) | ||||||||||||
| Yes | 72 (87) | 46 (87) | >.99 | 73 (95) | 27 (93) | .66 | 67 (99) | 28 (97) | .51 | 70 (100) | 20 (100) | >.99 |
| No | 11 (13) | 7 (13) | 4 (5) | 2 (7) | 1 (1) | 1 (3) | 0 (0) | 0 (0) | ||||
| . | 0–2 y Since 1st Dose (n = 136) . | 2–3 y Since 1st Dose (n = 108) . | 3–4 y Since 1st Dose (n = 97) . | 4–4½ y Since 1st Dose (n = 90) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | 3 Doses (n = 83) . | 2 Doses (n = 53) . | P Value . | 3 Doses (n = 77) . | 2 Doses (n = 29) . | P Value . | 3 Doses (n = 68) . | 2 Doses (n = 29) . | P Value . | 3 Doses (n = 70) . | 2 Doses (n = 20) . | P Value . |
| Current educational level, No. (%) | ||||||||||||
| Low | 14 (17) | 12 (23) | .49 | 11 (14) | 9 (31) | .23 | 9 (13) | 3 (10) | .82 | 4 (6) | 0 (0) | .45 |
| Middle | 21 (25) | 13 (25) | 22 (29) | 6 (21) | 24 (35) | 12 (41) | 32 (46) | 7 (35) | ||||
| High | 48 (58) | 27 (51) | 43 (56) | 14 (48) | 35 (51) | 14 (48) | 34 (49) | 13 (65) | ||||
| Unknown | 0 (0) | 1 (2) | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Country of birth, No. (%) | ||||||||||||
| Netherlands | 79 (100) | 49 (98) | .39 | 72 (97) | 26 (96) | .32 | 68 (100) | 28 (97) | .30 | 68 (97) | 17 (85) | .03 |
| Europe | 0 (0) | 0 (0) | 2 (3) | 0 (0) | 0 (0) | 1 (3) | 2 (3) | 1 (5) | ||||
| Other | 0 (0) | 1 (2) | 0 (0) | 1 (4) | 0 (0) | 0 (0) | 0 (0) | 2 (10) | ||||
| Country of birth mother, No. (%) | ||||||||||||
| Netherlands | 80 (96) | 45 (85) | .05 | 73 (95) | 22 (76) | <.01 | 65 (96) | 22 (76) | .01 | 63 (90) | 17 (85) | .70 |
| Europe | 1 (1) | 2 (4) | 3 (4) | 2 (7) | 1 (1) | 2 (7) | 3 (4) | 1 (5) | ||||
| Other | 2 (2) | 6 (11) | 1 (1) | 5 (17) | 2 (3) | 4 (14) | 4 (6) | 2 (10) | ||||
| Unknown | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | ||||
| Country of birth father, No. (%) | ||||||||||||
| Netherlands | 79 (95) | 45 (87) | .17 | 75 (97) | 18 (62) | <.01 | 66 (97) | 22 (76) | <.01 | 65 (93) | 15 (75) | .03 |
| Europe | 1 (1) | 1 (2) | 2 (3) | 2 (7) | 1 (1) | 1 (3) | 2 (3) | 0 (0) | ||||
| Other | 3 (4) | 6 (12) | 0 (0) | 8 (28) | 1 (1) | 5 (17) | 3 (4) | 5 (25) | ||||
| Unknown | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | ||||
| Oral contraceptive use, No. (%) | ||||||||||||
| Current user | 4 (5) | 4 (8) | .87 | 10 (13) | 9 (31) | .08 | 27 (40) | 14 (48) | .20 | 51 (73) | 13 (65) | .69 |
| Past user | 2 (2) | 1 (2) | 2 (3) | 0 (0) | 1 (1) | 2 (7) | 5 (7) | 1 (5) | ||||
| No | 77 (93) | 48 (91) | 65 (84) | 20 (69) | 40 (59) | 13 (45) | 14 (20) | 6 (30) | ||||
| Ever had sex, No. (%) | ||||||||||||
| Never | 82 (99) | 51 (96) | .56 | 71 (92) | 26 (90) | .43 | 57 (84) | 19 (66) | .06 | 37 (53) | 12 (60) | .62 |
| Yes | 1 (1) | 2 (4) | 6 (8) | 2 (7) | 11 (16) | 10 (34) | 33 (47) | 8 (40) | ||||
| Don’t know | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Age at sexual debut, median (range), y | 15 (15-15) | 14 (14-14) | .16 | 14 (13–15) | 14.5 (14–15) | .82 | 15 (13–16) | 15 (15-15) | .90 | 15 (12–16) | 16 (13–17) | .37 |
| Immuuncompromised, No. (%) | ||||||||||||
| No | 82 (99) | 53 (100) | >.99 | 77 (100) | 29 (100) | >.99 | 68 (100) | 29 (100) | >.99 | 70 (100) | 20 (100) | >.99 |
| Yes | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Don’t Know | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Immuunsupressive medication, No. (%) | ||||||||||||
| No | 79 (95) | 53 (100) | .41 | 74 (96) | 29 (100) | .56 | 61 (90) | 29 (100) | .27 | 67 (96) | 19 (95) | >.99 |
| Yes | 2 (2) | 0 (0) | 0 (0) | 0 (0) | 4 (6) | 0 (0) | 0 (0) | 0 (0) | ||||
| Don’t know | 2 (2) | 0 (0) | 3 (4) | 0 (0) | 3 (4) | 0 (0) | 3 (4) | 1 (5) | ||||
| Had menarche, No. (%) | ||||||||||||
| Yes | 72 (87) | 46 (87) | >.99 | 73 (95) | 27 (93) | .66 | 67 (99) | 28 (97) | .51 | 70 (100) | 20 (100) | >.99 |
| No | 11 (13) | 7 (13) | 4 (5) | 2 (7) | 1 (1) | 1 (3) | 0 (0) | 0 (0) | ||||
aData in Table 2 represent only participants who filled out the questionnaire.
Sociodemographic Characteristics of Participants Stratified by Dosing Schedulea
| . | 0–2 y Since 1st Dose (n = 136) . | 2–3 y Since 1st Dose (n = 108) . | 3–4 y Since 1st Dose (n = 97) . | 4–4½ y Since 1st Dose (n = 90) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | 3 Doses (n = 83) . | 2 Doses (n = 53) . | P Value . | 3 Doses (n = 77) . | 2 Doses (n = 29) . | P Value . | 3 Doses (n = 68) . | 2 Doses (n = 29) . | P Value . | 3 Doses (n = 70) . | 2 Doses (n = 20) . | P Value . |
| Current educational level, No. (%) | ||||||||||||
| Low | 14 (17) | 12 (23) | .49 | 11 (14) | 9 (31) | .23 | 9 (13) | 3 (10) | .82 | 4 (6) | 0 (0) | .45 |
| Middle | 21 (25) | 13 (25) | 22 (29) | 6 (21) | 24 (35) | 12 (41) | 32 (46) | 7 (35) | ||||
| High | 48 (58) | 27 (51) | 43 (56) | 14 (48) | 35 (51) | 14 (48) | 34 (49) | 13 (65) | ||||
| Unknown | 0 (0) | 1 (2) | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Country of birth, No. (%) | ||||||||||||
| Netherlands | 79 (100) | 49 (98) | .39 | 72 (97) | 26 (96) | .32 | 68 (100) | 28 (97) | .30 | 68 (97) | 17 (85) | .03 |
| Europe | 0 (0) | 0 (0) | 2 (3) | 0 (0) | 0 (0) | 1 (3) | 2 (3) | 1 (5) | ||||
| Other | 0 (0) | 1 (2) | 0 (0) | 1 (4) | 0 (0) | 0 (0) | 0 (0) | 2 (10) | ||||
| Country of birth mother, No. (%) | ||||||||||||
| Netherlands | 80 (96) | 45 (85) | .05 | 73 (95) | 22 (76) | <.01 | 65 (96) | 22 (76) | .01 | 63 (90) | 17 (85) | .70 |
| Europe | 1 (1) | 2 (4) | 3 (4) | 2 (7) | 1 (1) | 2 (7) | 3 (4) | 1 (5) | ||||
| Other | 2 (2) | 6 (11) | 1 (1) | 5 (17) | 2 (3) | 4 (14) | 4 (6) | 2 (10) | ||||
| Unknown | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | ||||
| Country of birth father, No. (%) | ||||||||||||
| Netherlands | 79 (95) | 45 (87) | .17 | 75 (97) | 18 (62) | <.01 | 66 (97) | 22 (76) | <.01 | 65 (93) | 15 (75) | .03 |
| Europe | 1 (1) | 1 (2) | 2 (3) | 2 (7) | 1 (1) | 1 (3) | 2 (3) | 0 (0) | ||||
| Other | 3 (4) | 6 (12) | 0 (0) | 8 (28) | 1 (1) | 5 (17) | 3 (4) | 5 (25) | ||||
| Unknown | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | ||||
| Oral contraceptive use, No. (%) | ||||||||||||
| Current user | 4 (5) | 4 (8) | .87 | 10 (13) | 9 (31) | .08 | 27 (40) | 14 (48) | .20 | 51 (73) | 13 (65) | .69 |
| Past user | 2 (2) | 1 (2) | 2 (3) | 0 (0) | 1 (1) | 2 (7) | 5 (7) | 1 (5) | ||||
| No | 77 (93) | 48 (91) | 65 (84) | 20 (69) | 40 (59) | 13 (45) | 14 (20) | 6 (30) | ||||
| Ever had sex, No. (%) | ||||||||||||
| Never | 82 (99) | 51 (96) | .56 | 71 (92) | 26 (90) | .43 | 57 (84) | 19 (66) | .06 | 37 (53) | 12 (60) | .62 |
| Yes | 1 (1) | 2 (4) | 6 (8) | 2 (7) | 11 (16) | 10 (34) | 33 (47) | 8 (40) | ||||
| Don’t know | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Age at sexual debut, median (range), y | 15 (15-15) | 14 (14-14) | .16 | 14 (13–15) | 14.5 (14–15) | .82 | 15 (13–16) | 15 (15-15) | .90 | 15 (12–16) | 16 (13–17) | .37 |
| Immuuncompromised, No. (%) | ||||||||||||
| No | 82 (99) | 53 (100) | >.99 | 77 (100) | 29 (100) | >.99 | 68 (100) | 29 (100) | >.99 | 70 (100) | 20 (100) | >.99 |
| Yes | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Don’t Know | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Immuunsupressive medication, No. (%) | ||||||||||||
| No | 79 (95) | 53 (100) | .41 | 74 (96) | 29 (100) | .56 | 61 (90) | 29 (100) | .27 | 67 (96) | 19 (95) | >.99 |
| Yes | 2 (2) | 0 (0) | 0 (0) | 0 (0) | 4 (6) | 0 (0) | 0 (0) | 0 (0) | ||||
| Don’t know | 2 (2) | 0 (0) | 3 (4) | 0 (0) | 3 (4) | 0 (0) | 3 (4) | 1 (5) | ||||
| Had menarche, No. (%) | ||||||||||||
| Yes | 72 (87) | 46 (87) | >.99 | 73 (95) | 27 (93) | .66 | 67 (99) | 28 (97) | .51 | 70 (100) | 20 (100) | >.99 |
| No | 11 (13) | 7 (13) | 4 (5) | 2 (7) | 1 (1) | 1 (3) | 0 (0) | 0 (0) | ||||
| . | 0–2 y Since 1st Dose (n = 136) . | 2–3 y Since 1st Dose (n = 108) . | 3–4 y Since 1st Dose (n = 97) . | 4–4½ y Since 1st Dose (n = 90) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | 3 Doses (n = 83) . | 2 Doses (n = 53) . | P Value . | 3 Doses (n = 77) . | 2 Doses (n = 29) . | P Value . | 3 Doses (n = 68) . | 2 Doses (n = 29) . | P Value . | 3 Doses (n = 70) . | 2 Doses (n = 20) . | P Value . |
| Current educational level, No. (%) | ||||||||||||
| Low | 14 (17) | 12 (23) | .49 | 11 (14) | 9 (31) | .23 | 9 (13) | 3 (10) | .82 | 4 (6) | 0 (0) | .45 |
| Middle | 21 (25) | 13 (25) | 22 (29) | 6 (21) | 24 (35) | 12 (41) | 32 (46) | 7 (35) | ||||
| High | 48 (58) | 27 (51) | 43 (56) | 14 (48) | 35 (51) | 14 (48) | 34 (49) | 13 (65) | ||||
| Unknown | 0 (0) | 1 (2) | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Country of birth, No. (%) | ||||||||||||
| Netherlands | 79 (100) | 49 (98) | .39 | 72 (97) | 26 (96) | .32 | 68 (100) | 28 (97) | .30 | 68 (97) | 17 (85) | .03 |
| Europe | 0 (0) | 0 (0) | 2 (3) | 0 (0) | 0 (0) | 1 (3) | 2 (3) | 1 (5) | ||||
| Other | 0 (0) | 1 (2) | 0 (0) | 1 (4) | 0 (0) | 0 (0) | 0 (0) | 2 (10) | ||||
| Country of birth mother, No. (%) | ||||||||||||
| Netherlands | 80 (96) | 45 (85) | .05 | 73 (95) | 22 (76) | <.01 | 65 (96) | 22 (76) | .01 | 63 (90) | 17 (85) | .70 |
| Europe | 1 (1) | 2 (4) | 3 (4) | 2 (7) | 1 (1) | 2 (7) | 3 (4) | 1 (5) | ||||
| Other | 2 (2) | 6 (11) | 1 (1) | 5 (17) | 2 (3) | 4 (14) | 4 (6) | 2 (10) | ||||
| Unknown | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | ||||
| Country of birth father, No. (%) | ||||||||||||
| Netherlands | 79 (95) | 45 (87) | .17 | 75 (97) | 18 (62) | <.01 | 66 (97) | 22 (76) | <.01 | 65 (93) | 15 (75) | .03 |
| Europe | 1 (1) | 1 (2) | 2 (3) | 2 (7) | 1 (1) | 1 (3) | 2 (3) | 0 (0) | ||||
| Other | 3 (4) | 6 (12) | 0 (0) | 8 (28) | 1 (1) | 5 (17) | 3 (4) | 5 (25) | ||||
| Unknown | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | ||||
| Oral contraceptive use, No. (%) | ||||||||||||
| Current user | 4 (5) | 4 (8) | .87 | 10 (13) | 9 (31) | .08 | 27 (40) | 14 (48) | .20 | 51 (73) | 13 (65) | .69 |
| Past user | 2 (2) | 1 (2) | 2 (3) | 0 (0) | 1 (1) | 2 (7) | 5 (7) | 1 (5) | ||||
| No | 77 (93) | 48 (91) | 65 (84) | 20 (69) | 40 (59) | 13 (45) | 14 (20) | 6 (30) | ||||
| Ever had sex, No. (%) | ||||||||||||
| Never | 82 (99) | 51 (96) | .56 | 71 (92) | 26 (90) | .43 | 57 (84) | 19 (66) | .06 | 37 (53) | 12 (60) | .62 |
| Yes | 1 (1) | 2 (4) | 6 (8) | 2 (7) | 11 (16) | 10 (34) | 33 (47) | 8 (40) | ||||
| Don’t know | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Age at sexual debut, median (range), y | 15 (15-15) | 14 (14-14) | .16 | 14 (13–15) | 14.5 (14–15) | .82 | 15 (13–16) | 15 (15-15) | .90 | 15 (12–16) | 16 (13–17) | .37 |
| Immuuncompromised, No. (%) | ||||||||||||
| No | 82 (99) | 53 (100) | >.99 | 77 (100) | 29 (100) | >.99 | 68 (100) | 29 (100) | >.99 | 70 (100) | 20 (100) | >.99 |
| Yes | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Don’t Know | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| Immuunsupressive medication, No. (%) | ||||||||||||
| No | 79 (95) | 53 (100) | .41 | 74 (96) | 29 (100) | .56 | 61 (90) | 29 (100) | .27 | 67 (96) | 19 (95) | >.99 |
| Yes | 2 (2) | 0 (0) | 0 (0) | 0 (0) | 4 (6) | 0 (0) | 0 (0) | 0 (0) | ||||
| Don’t know | 2 (2) | 0 (0) | 3 (4) | 0 (0) | 3 (4) | 0 (0) | 3 (4) | 1 (5) | ||||
| Had menarche, No. (%) | ||||||||||||
| Yes | 72 (87) | 46 (87) | >.99 | 73 (95) | 27 (93) | .66 | 67 (99) | 28 (97) | .51 | 70 (100) | 20 (100) | >.99 |
| No | 11 (13) | 7 (13) | 4 (5) | 2 (7) | 1 (1) | 1 (3) | 0 (0) | 0 (0) | ||||
aData in Table 2 represent only participants who filled out the questionnaire.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
